Translating Therapies for Huntington's Disease from Genetic Animal Models to Clinical Trials

NeuroRx

Volumn 1, Issue 3, 2004, Pages 298-306

  Hersch, Steven M ^a   Ferrante, Robert J ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c 74 Fenwood Road   (United States)

Author keywords

clinical trials; Huntington's disease; neurodegenerative; neuroprotection; therapy; transgenic mice

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; EXPERIMENTAL MODEL; GENETIC DISORDER; GENETIC MODEL; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; NONHUMAN; TRANSGENIC MOUSE; ANIMAL; BIOLOGICAL MODEL; DISEASE MODEL; GENETICS; MOUSE; REVIEW;

NEUROPROTECTIVE AGENT;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MODELS, GENETIC; NEUROPROTECTIVE AGENTS;

EID: 18844447024     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.1.3.298     Document Type: Article

References (39)

1. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996) 493-506
2. Hockly E., Woodman B., Mahal A., Lewis C., and Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull 61 (2003) 469-479
3. Schilling G., Becher M., Sharp A., Jinnah H., Duan K., Kotzuk J., et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8 (1999) 397-407
4. Yu Z., Li S., Evans J., Pillarisetti A., Li H., and Li X. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci 23 (2003) 2193-2202
5. Andreassen O., Dedeoglu A., Ferrante R., Jenkins B., Ferrante K., Thomas M., et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis 8 (2001) 479-491
6. Andreassen O., Ferrante R., Huang H., Dedeoglu A., Park L., Ferrante K., et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 50 (2001) 112-117
7. Andreassen O., Ferrante R., Dedeoglu A., and Beal M. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. NeuroReport 12 (2001) 3371-3373
8. Schilling G., Coonfield M., Ross C., and Borchelt D. Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett 315 (2001) 149-153
9. Ferrante R., Andreassen O., Dedeoglu A., Ferrante K., Jenkins B., Hersch S., et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22 (2002) 1592-1599
10. Klivenyi P., Ferrante R., Gardian G., Browne S., Chabrier P., and Beal M. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. J Neurochem 86 (2003) 267-272
11. Duan W., Guo Z., Jiang H., Ware M., Li X., and Mattson M. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci USA 100 (2003) 2911-2916
12. Reddy P., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell WO J., et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 20 (1998) 198-202
13. Slow E., van Raamsdonk J., Rogers D., Coleman S., Graham R., Deng Y., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 12 (2003) 1555-1567
14. Li C., Yang W., Gong S., and Heintz N. Transgenic mouse models of full-length Huntington's disease gene with BAC modification models. Soc Neurosci Abstr (2003) 130.9
15. Lin C., Tallaksen-Greene S., Chien W., Cearley J., Jackson W., Crouse A., et al. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10 (2001) 137-144
16. Shelbourne P., Killeen N., Hevner R., Johnston H., Tecott L., Lewandoski M., et al. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 8 (1999) 763-774
17. Wheeler V., White J., Gutekunst C., Vrbanac V., Weaver M., Li X., et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 9 (2000) 503-513
18. Wheeler V., Gutekunst C., Vrbanac V., Lebel L., Schilling G., Hersch S., et al. Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Hum Mol Genet 11 (2002) 633-640
19. Menalled L., Sison J., Dragatsis I., Zeitlin S., and Chesselet M. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J Comp Neurol 465 (2003) 11-26
20. Hockly E., Cordery P., Woodman B., Mahal A., van Dellen A., Blakemore C., et al. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 51 (2002) 235-242
21. Dedeoglu A., Kubilus J., Yang L., Ferrante K., Hersch S., Beal M., et al. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 85 (2003) 1359-1367
22. Rogers D., Jones D., Nelson P., Jones C., Quilter C., Robinson T., et al. Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains. Behav Brain Res 105 (1999) 207-217
23. Rogers D., Peters J., Martin J., Ball S., Nicholson S., Witherden A., et al. SHIRPA, a protocol for behavioral assessment: validation for longitudinal study of neurological dysfunction in mice. Neurosci Lett 306 (2001) 89-92
24. Dedeoglu A., Kubilus J., Jeitner T., Matson S., Bogdanov M., Kowall N., et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22 (2002) 8942-8950
25. Ferrante R., Kubilus J., Lee J., Ryu H., Beesen A., Zucker B., et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23 (2003) 9418-9427
26. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57 (2001) 397-404
27. Konig A. A framework for designing transgenic crops-science, safety and citizen's concerns. Nat Biotechnol 21 (2003) 1274-1279
28. Vaddadi K., Soosai E., Chiu E., and Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. NeuroReport 13 (2002) 29-33
29. Ravina B., Fagan S., Hart R., Hovinga C., Murphy D., Dawson T., et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 60 (2003) 1234-1240
30. Karpuj M., Becher M., Springer J., Chabas D., Youssef S., Pedotti R., et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8 (2002) 143-149
31. Mastroberardino P., Iannicola C., Nardacci R., Bernassola F., De Laurenzi V., Melino G., et al. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9 (2002) 873-880
32. Altman D., Schulz K., Mosher D., Eggar M., Davidoff F., Elbourne D., et al. The revised CONSORT statement for reporting randomized trials: explanations and elaboration. Ann Intern Med 134 (2001) 663-694
33. Chen M., Ona V., Li M., Ferrante R., Fink K., Zhu S., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6 (2000) 797-801
34. Smith D., Woodman B., Mahal A., Sathasivam K., Ghazi-Noori S., Lowden P., et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 54 (2003) 186-196
35. Ferrante R., Kubilus J., Kugars K., Rubinsztein D., Ryu H., Lee J., et al. Therapeutic effects of mithramycin in R6/2 transgenic Huntington's disease mice. Soc Neurosci Abstr 28 (2002)
36. Ona V., Li M., Vonsattel J., Andrews L., Khan S., Chung W., et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. Nature 399 (1999) 263-267
37. Ferrante R., Andreassen O., Jenkins B., Dedeoglu A., Kuemmerle S., Kubilus J., et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 20 (2000) 4389-4397
38. Sanchez I., Mahlke C., and Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 (2003) 373-379
39. Schiefer J., Landwehrmeyer G., Luesse H., Sprunken A., Puls C., Milkereit A., et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease. Mov Disord 17 (2002) 748-757